A new study opens the door for new treatments to help treat obesity and other eating disorders.
Researchers have identified specific chemical changes in the brain that drive nicotine addiction. The findings could lead to new treatments to help break the addiction.
Researchers have crystallized a protein that could hold the answer as to how nicotine addiction occurs in the brain.
Mouse study reveals neonatal nicotine exposure primes the ventral tegmental area, making the animals more susceptible to the effects of nicotine when exposed again later in life.
Researchers have engineered a new enzyme that breaks down nicotine in the bloodstream before it reaches the brain. The treatment reduces the urge to smoke and reverses signs of nicotine dependence, preventing relapse.
Researchers have identified a genetic variant associated with an increased risk of nicotine dependence.
Higher polygenetic risk scores for schizophrenia, depression, neuroticism, and alcohol use disorder are indicators for higher risk of nicotine dependence.
Researchers are developing a drug that enhances the function of nicotinic acetylcholine receptors. The drug could have three different applications in relieving pain, slowing memory loss in aging people and as a smoking cessation medication.
According to a new study, nicotine reduces dorsal striatal output, underlying the urge to smoke and making it difficult to quite the addiction.
Researchers determine how small changes in a particular region of the genome can alter nicotine consumption.